Drug Trial Radar · NCT03792919
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Dec 1, 2018
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Humanity & Health Medical Group LimitedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Conditions
- Chronic Hepatitis B
Interventions
Stop current treatment (anti-HBV neucleos(t)ides)Drug
Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Keep current treatment (anti-HBV neucleos(t)ides)Drug
Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of HBsAg clearanceTime frame: From baseline to the end of the fifth year after cessation of anti-HBV treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Humanity & Health Research Centre
Hong Kong, Hong Kong SAR, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.